Key result
Lipid-lowering therapy in a real-world ACS cohort was frequently suboptimal, with 38.9% of patients achieving the previous LDL-C goal but failing to meet the new 2019 ESC/EAS target of </dl.
Why the study?
The 2019 ESC/EAS guidelines recommended lower LDL-C targets for very high-risk patients, but attainment in real-world ACS populations in relation to lipid-lowering treatments was uninvestigated.
Observational (n=221)
No
A significant treatment gap exists in achieving the stricter 2019 ESC/EAS LDL-C targets in ACS patients, highlighting the need for more aggressive lipid-lowering therapy intensification and combination therapies.
Answers are grounded in this paper and cite their sources.
Real-world LDL-C target attainment lags post-event; leaves open optimal implementation strategies in very high-risk ASCVD.
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality in Europe.1 Patients surviving their first cardiovascular event are at increased risk of recurrence and classified as very high risk for cardiovascular events.2 The 2019 Joint European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines on dyslipidaemias recommend a low-density lipoprotein cholesterol (LDL-C) value of <55 mg/dl and LDL-C reduction of ≥50% from baseline in secondary prevention for patients at very high risk.3 The aim of this study was to investigate the attainment of the new LDL-C goal in a real-world acute coronary syndrome (ACS) population, in relation to the given lipid-lowering treatments (LLT). LLT intensity was divided into categories as follows: I = low-moderate-intensity statin only (∼30% effect on LDL-C); II = low-moderate statin plus ezetimibe (∼45% effect on LDL-C); III = high-intensity statin only (∼50% effect on LDL-C); IV = high-intensity statin plus ezetimibe (∼65% effect on LDL-C); and V = high-intensity statin plus ezetimibe plus Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (∼85% effect on LDL-C). Also, atorvastatin dose equivalents were calculated.6 The study was approved by the local ethics committee and was carried out under the Declaration of Helsinki. (a) Scatter plot showing correlation between projected baseline low-density lipoprotein (LDL) value and LDL difference with one year LDL (Pearson r = 0.72, p < 0.001), R2 = 0.515, analysis of variance (ANOVA) p = 0.000, B = 0.78 ± 0.5 (95% confidence interval (CI) 0.675–0.876). (b) Pie-chart showing lipid-lowering treatment (LLT) distribution across the acute coronary syndrome (ACS) population at one-year follow-up. (c) Pie-chart showing the statin use distribution across the ACS population at one-year follow-up. (d) Bar chart showing atorvastatin doses equivalents at different time periods. (e) Pie-chart showing LLT for non-attainers. Category I: low-moderate-intensity statin only; category II: low-moderate statin plus ezetimibe; category III: high-intensity statin only; category IV: high-intensity statin plus ezetimibe; category V: high-intensity statin plus ezetimibe plus proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. (a) Scatter plot showing correlation between projected baseline low-density lipoprotein (LDL) value and LDL difference with one year LDL (Pearson r = 0.72, p < 0.001), R2 = 0.515, analysis of variance (ANOVA) p = 0.000, B = 0.78 ± 0.5 (95% confidence interval (CI) 0.675–0.876). (b) Pie-chart showing lipid-lowering treatment (LLT) distribution across the acute coronary syndrome (ACS) population at one-year follow-up. (c) Pie-chart showing the statin use distribution across the ACS population at one-year follow-up. (d) Bar chart showing atorvastatin doses equivalents at different time periods. (e) Pie-chart showing LLT for non-attainers. Category I: low-moderate-intensity statin only; category II: low-moderate statin plus ezetimibe; category III: high-intensity statin only; category IV: high-intensity statin plus ezetimibe; category V: high-intensity statin plus ezetimibe plus proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Baseline characteristics based on absolute low-density lipoprotein cholesterol (LDL-C) goal attainment. BMI: body mass index; CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MI: myocardial infarction; PAD: peripheral artery disease; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction; TC: total cholesterol; TG: triglycerides. Variables with p < 0.25 at univariate analysis were inducted in the multivariate analysis. *p<0.05, **p<0.01, ***p<0.001. Baseline characteristics based on absolute low-density lipoprotein cholesterol (LDL-C) goal attainment. BMI: body mass index; CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MI: myocardial infarction; PAD: peripheral artery disease; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction; TC: total cholesterol; TG: triglycerides. Variables with p < 0.25 at univariate analysis were inducted in the multivariate analysis. *p<0.05, **p<0.01, ***p<0.001. Of note, about half of the patients (51.6%, p < 0.0001) achieved the previously recommended goal of LDL-C <70 mg/dl or ≥50% LDL-C reduction from baseline levels. Eighty-six patients (38.9%) achieved the old goal, but not the new one. Of these, 18.6%, 4.7%, 61.6%, 11.6% and 1.7% were on LLT category I, II, III, IV and V respectively. Statin use before the index event was reported by 64/221 patients and the equivalent atorvastatin dose was 21.7 ± 13.1 mg. Of the patients, 86% were prescribed a high-intensity statin at discharge. Two hundred and fifteen patients (97.3%) reported taking LLT at the one-year follow-up (Figure 1(b)). LLT compared to that at discharge was down-titrated in 17.2% and up-titrated in 9.3% of patients. The atorvastatin equivalent dose was 33.8 ± 12.0 mg (Figure 1(c) and (d)). Twelve months post-ACS, 74.9% of patients were on intense LLT, namely high-intensity statin ± ezetimibe ± PCSK9 inhibitor, regardless of the baseline LDL-C values. Higher baseline LDL-C values were not associated with increased intensity of the LLT (p = 0.069), thus LLT was not appropriately up-titrated. No differences between LLT categories have been observed regarding the target value attainment. Of non-attainers, 64.2% are eligible for ezetimibe and 8.6% for PCSK9 inhibitor adjunction (Figure 1(e)). Patients on category III LLT had significantly lower follow-up LDL-C levels than patients on category I LLT (69 (55–86) mg/dl vs 78 (60–108) mg/dl, p = 0.044). At one-year follow-up, cardiovascular health outcomes (myocardial infarction, stroke, admission for unstable angina and need for percutaneous coronary intervention (PCI)) were observed in 14 patients (6.3%, p = 0.521 for LDL-C goal). According to the latest ESC/EAS guidelines, for patients experiencing a new vascular event in the two years after the index event, while taking maximally tolerated statin-based therapy, an LDL-C goal of <40 mg/dl may be considered (class of recommendation IIb).3 Ten patients were on category IV LLT, three on category I LLT and one patient did not report LLT. None of 10 patients achieved the recommended goal. The new European guidelines recommended for the first time such low levels of LDL-C and, hence, target value attainment is more challenging than before.7 High-intensity treatment for ≈50% reduction of baseline LDL-C after an ACS is imperative as a first-step approach. As shown, patients’ equivalent atorvastatin dose rises after an ACS, with rates comparable to previously reported data.8 Nevertheless, LLT remains suboptimal and not appropriate for goal attainment even after a major revascularisation event, such as coronary-artery bypass graft surgery.9 This could be attributed to the ‘adverse events' of statins (e.g. statin-associated muscle symptoms and mild elevation of alanine transaminase (ALT)), which impede not only patients’ adherence, but up-titration of LLT by caregivers as well.10,11 In our cohort, merely four out of 10 patients, who achieved the previously recommended goal, are now out of goal attainment and in need of up-titration of LLT. Subsequently, combination therapies emerge to be essential with greater frequency, in order to achieve the recommended proportional reduction of baseline LDL-C and especially in patients with higher baseline LDL-C values; yet still, in our study, 8.4% of patients were on a high statin plus ezetimibe combination and only one patient was receiving a PCSK9 inhibitor. Truly, the cost-effectiveness of PCSK9 inhibitors is an issue, but data supporting improved cost-effectiveness in selected high risk patients without serious adverse events exists.12 In addition, cardiac rehabilitation programmes have been shown to have a positive impact on LDL-C goal attainment and should be implemented with greater frequency.13 Last, but not least, patients achieving goals should be further assessed for achievement of secondary goals (non-HDL-C, Apolipoprotein B).3 Our study has the limitation of an observational study with a small number of patients. Also, data was collected in the context of a clinical trial, therefore that could positively affect lipid goal attainment. However, data were prospectively collected and are robust due to the single-centre nature of the study. Our data was collected before the publication of the new LDL-C goal for very high risk patients, but results show the work to be done in the secondary prevention field. In conclusion, far fewer ACS patients achieved the new LDL-C goal at one-year follow-up, creating a treatment gap with conventional drugs. LLT remained poorly titrated at follow-up, despite its improvement after the index event. This study demonstrates the need for long-term intensification of LLT in very high risk patients, to achieve the new LDL-C targets and maximise secondary prevention.
No takes yet. Share an insight, caveat, or question.
Farmakis et al. (2019) conducted an observational in Acute coronary syndrome (n=221). Lipid-lowering therapy vs. Lower intensity lipid-lowering therapy or no therapy was evaluated on Attainment of the new LDL-C goal (<55 mg/dl and ≥50% reduction from baseline). Lipid-lowering therapy in a real-world ACS cohort was frequently suboptimal, with 38.9% of patients achieving the previous LDL-C goal but failing to meet the new 2019 ESC/EAS target of </dl.
Synapse has enriched 10 related papers. Consider them for comparative context: